ARA-290 Benefits: Claims vs What Studies Show
Benefits people claim for ARA-290, set against what published studies measured, and where no study exists.
- Strongest evidence
- Human RCT
- Human / animal studies
- 5 / 6
- in our evidence file (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
- research chemical
Claimed benefits and what studies show
Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Claim | Best evidence | Studies (human / animal) | What was measured | Page |
|---|---|---|---|---|
| Neuropathy | Human RCT evidence, 4 of 4 | 3 / 2 | Corneal nerve fiber area (4 mg); Pain; Neuropathic symptoms | Evidence for neuropathy |
| Eyes and vision | Human observational evidence, 3 of 4 | 1 / 0 | Visual acuity and retinal thickness | Evidence for eyes and vision |
| Inflammation | Animal evidence, 2 of 4 | 0 / 2 | Colitis course; Disease severity | Evidence for inflammation |
| Healing | Animal evidence, 2 of 4 | 0 / 1 | Diabetic wound healing | None |
| Skin | Animal evidence, 2 of 4 | 0 / 1 | Diabetic wound healing | Evidence for skin |
| Gut health | Animal evidence, 2 of 4 | 0 / 1 | Colitis course | Evidence for gut health |
| Immune system | Animal evidence, 2 of 4 | 0 / 1 | Disease severity | Evidence for immune system |
Strongest study per claim: Neuropathy, Investigative ophthalmology & visual science 2017, PMID 28475703; Eyes and vision, Journal of clinical medicine 2020, PMID 32674280; Inflammation, Scientific reports 2017, PMID 29026145.
What the studies measured
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Corneal nerve fiber area (4 mg) | Placebo-corrected corneal nerve fiber area change at day 28 was 109 (1 mg), 697 (4 mg, P = 0.012) and 431 (8 mg); only the 4 mg group reached significance. | Human RCTn = 64 | Investigative ophthalmology & visual science 2017, PMID 28475703 |
| Pain | Pain improved in all groups; the placebo-corrected decrease in the 4 mg group among those with moderate-severe pain was not statistically significant (P = 0.157). | Human RCTn = 64 | Investigative ophthalmology & visual science 2017, PMID 28475703 |
| Metabolic control | The ARA 290 group showed improved HbA1c and lipid profiles over the 56-day observation period. | Human controlled trial | Molecular medicine 2015, PMID 25387363 |
| Neuropathic symptoms | PainDetect neuropathic symptom scores improved significantly with ARA 290. | Human controlled trial | Molecular medicine 2015, PMID 25387363 |
| Mood and affective symptoms | No effect on mood or affective symptoms in healthy volunteers. | Human RCTn = 36 | European neuropsychopharmacology 2015, PMID 26431906 |
| Small fiber neuropathy symptom score | The ARA 290 group improved significantly more than placebo on the small fiber neuropathy screening list score at week 4 (change -11.5 versus -2.9). | Human RCTn = 22 | Molecular medicine 2012, PMID 23168581 |
| Pain intensity (BPI) and fatigue | Brief Pain Inventory and fatigue scores improved in both groups, with no difference between treatment and placebo. | Human RCTn = 22 | Molecular medicine 2012, PMID 23168581 |
| Visual acuity and retinal thickness | No improvement in mean visual acuity, central retinal thickness, retinal sensitivity or tear production at week 12; the questionnaire composite improved. | Human uncontrolled trialn = 9 | Journal of clinical medicine 2020, PMID 32674280 |
| Plasma half-life | Review reports a short plasma half-life of about 2 minutes but sustained biological effects. | Review | Pharmacology & therapeutics 2015, PMID 25728128 |
| Diabetic wound healing | Cibinetide improved the poor re-epithelialization, angiogenesis and wound strength seen in diabetic mice. | Animal · mouse (genetic diabetes, db/db) (not a human result) | Biochimica et biophysica acta. Molecular basis of disease 2018, PMID 29223734 |
| Colitis course | Cibinetide improved weight gain and survival in mice with established DSS colitis. | Animal · mouse (not a human result) | Scientific reports 2017, PMID 29026145 |
| Disease severity | ARA290 reduced severity and duration of clinical score and spinal cord inflammation in EAE rats. | Animal · rat (not a human result) | Journal of neuroimmunology 2014, PMID 24518674 |
| Mechanical allodynia | ARA290 prevented the development of mechanical allodynia in the neuritis model; heat hyperalgesia was not significantly affected. | Animal · rat (not a human result) | Neuroscience 2013, PMID 23262243 |
| Renal function after ischemia/reperfusion | ARA290 increased glomerular filtration rate over the seven-day observation period in pigs. | Animal · pig (not a human result)n = 8 | Journal of translational medicine 2013, PMID 23302512 |
| Neuropathic pain (allodynia) | ARA290 gave long-term relief of tactile and cold allodynia in rats, lasting as long as 15 weeks. | Animal · rat and mouse (including beta-common receptor knockout mice) (not a human result)n = 8 | Anesthesiology 2011, PMID 21873879 |
Nerve pain and nerve fibres
The neuropathy claim rests on small human trials: in type 2 diabetes with painful neuropathy, ARA 290 4 mg daily for 28 days was followed by significant PainDetect improvement versus placebo.[2]
In a phase 2b sarcoidosis trial, cibinetide 4 mg a day raised corneal nerve fiber area by 697 square micrometres over placebo at day 28 (P = 0.012).[1]
Blood sugar, eyes and mood
In the same diabetes trial, HbA1c and lipid profiles improved in the ARA 290 group over the 56-day observation period.[2]
In the diabetic macular edema trial, visual acuity, retinal thickness and retinal sensitivity did not improve on average, while a vision-function questionnaire score did.[5]
In healthy volunteers given ARA290, no effects were observed on mood or affective symptoms, although some emotional-processing measures changed.[3]
Inflammation, gut and wound-healing claims (animals only)
In mice with chemically induced colitis, cibinetide improved weight gain and survival, an animal result.[8]
In mice with genetic diabetes, cibinetide improved wound re-epithelialisation, angiogenesis and breaking strength measures, again in animals.[7]
In rats with experimental autoimmune encephalomyelitis, ARA290 reduced clinical score severity and spinal cord inflammation, an animal model.[9]
More on ARA-290
Common questions
Is ARA-290 proven to work?
The strongest study we summarise for ARA-290 is human rct evidence, among 12 studies. A trial result is not an approval; see the legal status.
What does ARA 290 do?
It is an 11-amino-acid peptide modelled on erythropoietin that is designed to activate the innate repair receptor without raising red blood cell production.[6]
What has ARA 290 been studied for?
Published human trials tested it in sarcoidosis neuropathy, diabetic neuropathy and diabetic macular edema.[5]
More on ARA-290
Sources
- 1Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.Investigative ophthalmology & visual science · 2017PMID 28475703Accessed 2 Oct 2026
- 2ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Molecular medicine (Cambridge, Mass.) · 2015PMID 25387363Accessed 2 Oct 2026
- 3Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2015PMID 26431906Accessed 2 Oct 2026
- 4Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.Molecular medicine (Cambridge, Mass.) · 2012PMID 23168581Accessed 2 Oct 2026
- 5A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.Journal of clinical medicine · 2020PMID 32674280Accessed 2 Oct 2026
- 6Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.Pharmacology & therapeutics · 2015PMID 25728128Accessed 2 Oct 2026
- 7Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes.Biochimica et biophysica acta. Molecular basis of disease · 2018PMID 29223734Accessed 2 Oct 2026
- 8Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis.Scientific reports · 2017PMID 29026145Accessed 2 Oct 2026
- 9Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat.Journal of neuroimmunology · 2014PMID 24518674Accessed 2 Oct 2026
- 10The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model.Neuroscience · 2013PMID 23262243Accessed 2 Oct 2026
- 11ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury.Journal of translational medicine · 2013PMID 23302512Accessed 2 Oct 2026
- 12ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.Anesthesiology · 2011PMID 21873879Accessed 2 Oct 2026
- 13PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab]) (75 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab]) AND (sarcoidosis[tiab] OR neuropath*[tiab] OR patients[tiab] OR randomized[tiab]) (29 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 17PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab] OR pHBSP[tiab]) AND (patients[tiab] OR subjects[tiab] OR volunteers[tiab]) (18 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
Found an error? Report a correction.